معرفی
Filipe Pereira is a Professor and Senior Lecturer at Lund University's Faculty of Medicine, where he holds a Wallenberg Molecular Medicine Fellowship and leads the Cell Reprogramming in Hematopoiesis and Immunity research team within the Division of Molecular Medicine and Gene Therapy. His work contributes to UN Sustainable Development Goals related to health and well-being.
Dr. Pereira's research focuses on understanding the molecular determinants of cell reprogramming and hematopoietic specification. His laboratory investigates how cellular identities are specified during development, with particular emphasis on Hematopoietic Stem Cells (HSCs) for their regenerative potential and Dendritic Cells (DCs) as key orchestrators of immunity. The team explores experimental approaches to cell reprogramming including nuclear transfer, cell fusion, and transcription factor expression to develop new therapies for immune and blood diseases.
Analysis of Dr. Pereira's 98 research outputs reveals a strong focus on cellular reprogramming techniques for immunotherapy applications, particularly in cancer treatment. His work spans molecular biology, immunology, and stem cell research, with significant contributions to understanding transcription factor networks that control cell fate decisions. The research has practical applications in regenerative medicine and cancer immunotherapy, with several publications in high-impact journals including Nature Communications and Science Immunology.
Scientific Recognition:
- Imperial College Emerging Alumni Leader Award (2025)
- ERC Proof of Concept grant (2024)
- Pfizer-Portugal award in basic research (2024)
- ERC Proof of Concept Grant (2023)
- Eric K. Fernströms Prize to young particularly promising researchers (2023)
Dr. Pereira actively supervises graduate students and postdoctoral researchers, with 12 PhD students and 8 postdocs under his mentorship. He leads multiple research projects including 'In Vivo Dendritic Cell Reprogramming Immunotherapy' and 'Functional chemical reprogramming of cancer cells to induce antitumor immunity,' funded by organizations including the European Commission and Cancer Research Institute. His laboratory has developed innovative approaches to reprogram somatic cells into desired hematopoietic cell types, with significant implications for therapeutic applications.
The Cell Reprogramming in Hematopoiesis and Immunity team collaborates extensively across international boundaries, with research outputs picked up by numerous news outlets and referenced in patents and Wikipedia pages, demonstrating the broad impact of their work in the scientific community and beyond.
